Use of a lentil product to increase the bioavailability of non-haem iron in a composition comprising one or more anti-nutritional factors.

Use of a lentil product to increase the bioavailability of non-haem iron in a composition comprising one or more anti-nutritional factors.

Compositions comprising aldehyde functional monoterpenoids in combination with 3,3′,4′,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19, and/or enhancing mood.

Compositions comprising aldehyde functional monoterpenoids in combination with 3,3′,4′,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19, and/or enhancing mood.

Compositions comprising aldehyde functional monoterpenoids in combination with 3,3′,4′,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19, and/or enhancing mood.

The present disclosure is directed to dopamine producing probiotics to increase immune responses to vaccination and to provide increased immune protection. The present disclosure is further directed to dopamine producing synbiotic compositions, formulations, plants, and synthetic compounds and their use for targeted clinical and veterinary applications, for example, in promoting health and well-being and enhancing vaccine efficacy. The present disclosure also provides an approach for optimization of synbiotic delivery of a probiotic or other dopamine producing product with a dopamine precursor to beneficially aid in the use of such products for a variety of conditions and diseases, and particularly in the field of vaccines, whether prophylactic or therapeutic.

The present disclosure is directed to dopamine producing probiotics to increase immune responses to vaccination and to provide increased immune protection. The present disclosure is further directed to dopamine producing synbiotic compositions, formulations, plants, and synthetic compounds and their use for targeted clinical and veterinary applications, for example, in promoting health and well-being and enhancing vaccine efficacy. The present disclosure also provides an approach for optimization of synbiotic delivery of a probiotic or other dopamine producing product with a dopamine precursor to beneficially aid in the use of such products for a variety of conditions and diseases, and particularly in the field of vaccines, whether prophylactic or therapeutic.

The present disclosure is directed to dopamine producing probiotics to increase immune responses to vaccination and to provide increased immune protection. The present disclosure is further directed to dopamine producing synbiotic compositions, formulations, plants, and synthetic compounds and their use for targeted clinical and veterinary applications, for example, in promoting health and well-being and enhancing vaccine efficacy. The present disclosure also provides an approach for optimization of synbiotic delivery of a probiotic or other dopamine producing product with a dopamine precursor to beneficially aid in the use of such products for a variety of conditions and diseases, and particularly in the field of vaccines, whether prophylactic or therapeutic.

The present composition provides for mitigating adverse effects of alcohol consumption. The composition includes a fructose source comprising between 5% and 75% of a total weight of the composition, a niacinamide source comprising between 0.1% and 1% of the total weight, and a glycoprotein source comprising between 0.1% and 2% of the total weight, wherein the total weight is a weight prior to inclusion with a hydrating source. The composition can be disposed in a powder or dissolved form, as part of a concentrate, and/or part of a beverage. The composition can include mixability for diluting or mixing with the liquid or beverage for user consumption and absorprtion.

The present composition provides for mitigating adverse effects of alcohol consumption. The composition includes a fructose source comprising between 5% and 75% of a total weight of the composition, a niacinamide source comprising between 0.1% and 1% of the total weight, and a glycoprotein source comprising between 0.1% and 2% of the total weight, wherein the total weight is a weight prior to inclusion with a hydrating source. The composition can be disposed in a powder or dissolved form, as part of a concentrate, and/or part of a beverage. The composition can include mixability for diluting or mixing with the liquid or beverage for user consumption and absorprtion.